LET 2.5 (Letrozole 2.5 mg)
Pill imprint LET 2.5 has been identified as Letrozole 2.5 mg.
Letrozole is used in the treatment of female infertility; breast cancer, metastatic; breast cancer; breast cancer, adjuvant and belongs to the drug classes aromatase inhibitors, hormones/antineoplastics. There is positive evidence of human fetal risk during pregnancy. Letrozole 2.5 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- LET 2.5
- Strength:
- 2.5 mg
- Color:
- Yellow
- Shape:
- Round
- Availability:
- Prescription only
- Drug Class:
- Aromatase inhibitors
Hormones/antineoplastics - Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Dr. Reddy's Laboratories Limited
- National Drug Code (NDC):
- 55111-0646
- Inactive Ingredients:
- silicon dioxide colloidal
croscarmellose sodium
hypromelloses
lactose monohydrate
magnesium stearate
polyethylene glycol
povidone
magnesium silicate
titanium dioxide
ferric oxide yellow
More about letrozole
Consumer resources
- Other brands: Femara
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
